Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ciloprost
2. Ventavis
3. Zk 36374
4. Zk-36374
5. Zk36374
1. Ciloprost
2. Ventavis
3. Endoprost
4. Ilomedin
5. 78919-13-8
6. Iloprostum
7. Zk-36374
8. Jed5k35ygl
9. Zk 36374
10. Chembl494
11. Chebi:63916
12. Zk 00036374
13. (5e)-5-[(3as,4r,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]pentanoic Acid
14. [3h]-iloprost
15. Ventavis (tn)
16. Zk-00036374
17. 73873-87-7
18. (16r,s)-methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I2
19. 15(r)-iloprost
20. (5e)-5-[(3as,4r,5r,6as)-5-hydroxy-4-[(1e,3s)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1h)-ylidene]pentanoic Acid
21. Iloprostum [latin]
22. Sr-05000001498
23. Unii-jed5k35ygl
24. Iloprost [usan:inn:ban]
25. Ilomedine
26. Bay Q6256
27. Iloprost [usan]
28. Iloprost (usan/inn)
29. Iloprost [inn]
30. Iloprost [jan]
31. Iloprost [mi]
32. Iloprost [vandf]
33. Iloprost [mart.]
34. Iloprost [who-dd]
35. Iloprost [ema Epar]
36. Iloprost [orange Book]
37. Schembl6083382
38. Iloprost, >=98% (hplc)
39. Bay-q-6256
40. Dtxsid2041046
41. Bdbm23954
42. Hms2090a19
43. 85026-51-3
44. Ex-a6213
45. Hy-a0096
46. Sh-401
47. (16r,s)-methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)
48. Akos024456922
49. Cs-5586
50. Db01088
51. (e)-5-(3as,4r,5r,6as)-5-hydroxy-4((e)-(3s,4rs)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
52. Pentanoic Acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1h)-pentalenylidene)-
53. D02721
54. E-1030
55. Aceticacid2-tert-butyl-4-methylphenylester
56. J-502615
57. Sr-05000001498-1
58. Sr-05000001498-2
59. Brd-a45664787-001-01-4
60. Brd-a45664787-001-02-2
61. Q20817139
62. (1s,2r,3r,5s)-7-[(e)-4-carboxybutylidene]-2-[(3s,1e)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane
63. (5e)-(3as,4r,5r,6as)-5-hydroxy-4-((1e)-(3s,4rs)-3-hydroxy-4-methyloct-1-en-6-ynyl)-hexahydropentalen-2(1h)-ylidene)pentanoic Acid
64. (5e)-5-[(3as,4r,5r,6as)-hexahydro-5-hydroxy-4-[(1e,3s)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1h)-pentalenylidene]pentanoic Acid
65. (e)-(3as,4r,5r,6as)-hexahydro-5-hydroxy-4-((e)-(3s,4rs)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1h),delta)-pentalenevaleric Acid
66. (z)-5-((3as,4r,5r,6as)-5-hydroxy-4-((3s,e)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1h)-ylidene)pentanoic Acid
67. 5-[(2e,3as,4r,5r,6as)-5-hydroxy-4-[(1e,3s)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic Acid
68. Pentanoic Acid, 5-((3as,4r,5r,6as)-hexahydro-5-hydroxy-4-((1e,3s)-3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1h)-pentalenylidene)-, (5e)-
Molecular Weight | 360.5 g/mol |
---|---|
Molecular Formula | C22H32O4 |
XLogP3 | 2.8 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 8 |
Exact Mass | 360.23005950 g/mol |
Monoisotopic Mass | 360.23005950 g/mol |
Topological Polar Surface Area | 77.8 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 606 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Used for the treatment of pulmonary arterial hypertension.
FDA Label
Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms.
Iloprost is a synthetic analogue of prostacyclin PGI2 that dilates systemic and pulmonary arterial vascular beds. It was shown to affect platelet aggregation, but whether this effect contributes to its vasodilatory action has not been elucidated. There are two diastereoisomers of iloprost and the 4S isomer is reported to exhibit a higher potency in dilating blood vessels compared to the 4R isomer.
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
B01AC11
B01AC11
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
B - Blood and blood forming organs
B01 - Antithrombotic agents
B01A - Antithrombotic agents
B01AC - Platelet aggregation inhibitors excl. heparin
B01AC11 - Iloprost
Absorption
Rapidly absorbed with bioavailability of 63%
Volume of Distribution
0.7 to 0.8 L/kg
Clearance
20 mL/min/kg [Normal subjects]
Primarily hepatic. Iloprost is metabolized principally via beta-oxidation of the carboxyl side chain.
20-30 minutes
Iloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) and prostaglandin EP1 receptors. Iloprost constricts the ilium and fundus circular smooth muscle as strongly as prostaglandin E2 (PGE2) itself. Iloprost inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time. All of these properties help to antagonize the pathological changes that take place in the small pulmonary arteries of patients with pulmonary hypertension.
NDC Package Code : 82231-109
Start Marketing Date : 2018-09-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0017
Start Marketing Date : 2012-05-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
About the Company : Chirogate, established in 1999, is a leading supplier of niche-market molecules, specializing in prostaglandins. With a focus on quality and compliance, Chirogate has built a reput...
About the Company : EUROAPI is focused on reinventing active ingredient solutions to meet the needs of customers and patients worldwide sustainably. We are a leading player in APIs with approximately ...
About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : NEWCHEM is an independent Italian manufacturer of Active Pharmaceutical Ingredients (APIs) - Steroids, Progestogens, Prostafglandins. NEWCHEM is active on the worldwide Pharmaceut...
About the Company : Founded in 2000, YONSUNG fine chemicals co., Ltd. is a top quality, fast growing manufacturer of APIs, especially, PROSTAGLANDINS and related products for pharmaceutical applicatio...
About the Company : Founded in 2010, Ausun Pharmaceutical is a public company, specialized in high-tech. threshold Generic API Dev. & providing CDMO services. Ausun owns & operates 1 on-site R&D Cente...
Details:
Aurlumyn (iloprost) is a prostanoid IP receptor agonist, acts as vasodilator that opens blood vessels and stops blood clotting. It is indicated for the treatment of severe frostbite in adults.
Lead Product(s): Iloprost
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Aurlumyn
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2024
Lead Product(s) : Iloprost
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves First Medication to Treat Severe Frostbite
Details : Aurlumyn (iloprost) is a prostanoid IP receptor agonist, acts as vasodilator that opens blood vessels and stops blood clotting. It is indicated for the treatment of severe frostbite in adults.
Product Name : Aurlumyn
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Details:
The funding will support the initiative by Danish researchers and researchers from BioPorto A/S, to test if evaIloprost (prostacyclin) can potentially reduce damage to the capillaries and counteract ARDS to increase survival rates in COVID-19 patients.
Lead Product(s): Iloprost
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Other Small Molecule
Sponsor: Innovation Fund Denmark
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding May 14, 2020
Lead Product(s) : Iloprost
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Innovation Fund Denmark
Deal Size : $0.4 million
Deal Type : Funding
Danish Team of Researchers to Test Treatment of Critically Ill Patients Suffering from COVID-19
Details : The funding will support the initiative by Danish researchers and researchers from BioPorto A/S, to test if evaIloprost (prostacyclin) can potentially reduce damage to the capillaries and counteract ARDS to increase survival rates in COVID-19 patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 14, 2020
Details:
The AURORA study is a multicenter, double-blind, randomized, placebo-controlled, Phase 3 study evaluating the safety and efficacy of intravenous (IV) iloprost in patients with SSc experiencing symptomatic digital ischemic episodes (symptomatic Raynaud's Phenomenon).
Lead Product(s): Iloprost
Therapeutic Area: Immunology Brand Name: CIVI030
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 10, 2020
Lead Product(s) : Iloprost
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CiVi Biopharma Resumes AURORA Phase 3 Clinical Trial of CIVI030 to Treat Systemic Sclerosis
Details : The AURORA study is a multicenter, double-blind, randomized, placebo-controlled, Phase 3 study evaluating the safety and efficacy of intravenous (IV) iloprost in patients with SSc experiencing symptomatic digital ischemic episodes (symptomatic Raynaud's ...
Product Name : CIVI030
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2020
Related Excipient Companies
Excipients by Applications
Global Sales Information
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 20 mcg/ml
Price Per Pack (Euro) : 260.40
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Concentrate to the infusion flui...
Dosage Strength : 20 mcg/ml
Price Per Pack (Euro) : 415.73
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Iloprost 20Mcg 2Ml 30 Joined' Re...
Dosage Strength : 30 ampoules soluz nebul 2 ml 10 mcg/ml
Price Per Pack (Euro) : 1,411.09
Published in :
Country : Italy
RX/OTC/DISCN : Class A
Dosage Form : Iloprost 20Mcg 2Ml 90 Units Resp...
Dosage Strength : 3x30 vials nebul soluz 2 ml 10 mcg/ml
Price Per Pack (Euro) : 4,233.30
Published in :
Country : Italy
RX/OTC/DISCN : Class A
Dosage Form : Inf Konz
Dosage Strength : 20mcg/ml
Price Per Pack (Euro) : 33.85
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Dosage Form : Inf Konz
Dosage Strength : 50mcg/2.5ml
Price Per Pack (Euro) : 68.27
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Dosage Form : Inhal L?s
Dosage Strength : 20mcg/2ml
Price Per Pack (Euro) : 803.47
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Dosage Form : Inhalasjonsvaeske to nebulisator...
Dosage Strength : 10 mcg/ml
Price Per Pack (Euro) : 3,181.41
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Inhalasjonsvaeske to nebulisator...
Dosage Strength : 10 mcg/ml
Price Per Pack (Euro) : 3,222.93
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Inhalasjonsvaeske to nebulisator...
Dosage Strength : 10 mcg/ml
Price Per Pack (Euro) : 3,580.50
Published in :
Country : Norway
RX/OTC/DISCN :
Actelion
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 72
2015 Revenue in Millions : 104
Growth (%) : -30
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
Reply
05 Oct 2024
Reply
05 Aug 2022
Reply
29 Jan 2021
Reply
19 Jun 2020
Reply
14 May 2019
Patents & EXCLUSIVITIES
Exclusivity Code : NP
Exclusivity Expiration Date : 2027-02-13
Application Number : 217933
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-465
Exclusivity Expiration Date : 2031-02-13
Application Number : 217933
Product Number : 1
Exclusivity Details :
ABOUT THIS PAGE
68
PharmaCompass offers a list of Iloprost API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Iloprost manufacturer or Iloprost supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Iloprost manufacturer or Iloprost supplier.
PharmaCompass also assists you with knowing the Iloprost API Price utilized in the formulation of products. Iloprost API Price is not always fixed or binding as the Iloprost Price is obtained through a variety of data sources. The Iloprost Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ventavis manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ventavis, including repackagers and relabelers. The FDA regulates Ventavis manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ventavis API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ventavis manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ventavis supplier is an individual or a company that provides Ventavis active pharmaceutical ingredient (API) or Ventavis finished formulations upon request. The Ventavis suppliers may include Ventavis API manufacturers, exporters, distributors and traders.
click here to find a list of Ventavis suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ventavis DMF (Drug Master File) is a document detailing the whole manufacturing process of Ventavis active pharmaceutical ingredient (API) in detail. Different forms of Ventavis DMFs exist exist since differing nations have different regulations, such as Ventavis USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ventavis DMF submitted to regulatory agencies in the US is known as a USDMF. Ventavis USDMF includes data on Ventavis's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ventavis USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ventavis suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ventavis as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ventavis API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ventavis as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ventavis and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ventavis NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ventavis suppliers with NDC on PharmaCompass.
Ventavis Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ventavis GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ventavis GMP manufacturer or Ventavis GMP API supplier for your needs.
A Ventavis CoA (Certificate of Analysis) is a formal document that attests to Ventavis's compliance with Ventavis specifications and serves as a tool for batch-level quality control.
Ventavis CoA mostly includes findings from lab analyses of a specific batch. For each Ventavis CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ventavis may be tested according to a variety of international standards, such as European Pharmacopoeia (Ventavis EP), Ventavis JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ventavis USP).